atorvastatin has been researched along with Bile Duct Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahane, T; Kaji, K; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Nishimura, N; Saikawa, S; Sato, S; Yoshiji, H | 1 |
| Buranrat, B; Kukongviriyapan, V; Prawan, A; Senggunprai, L | 1 |
2 other study(ies) available for atorvastatin and Bile Duct Cancer
| Article | Year |
|---|---|
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Topics: Animals; Anticholesteremic Agents; Antimetabolites, Antineoplastic; Apoptosis; Atorvastatin; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Connective Tissue Growth Factor; Contractile Proteins; Cysteine-Rich Protein 61; Deoxycytidine; Drug Combinations; Drug Interactions; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Muscle Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-yes; Repressor Proteins | 2020 |
Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.
Topics: Apoptosis; Atorvastatin; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Reactive Oxygen Species; Simvastatin | 2016 |